pyrroles has been researched along with misonidazole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C | 1 |
| Barré, L; Bernaudin, M; Delamare, J; Divoux, D; Marteau, L; Petit, E; Roussel, S; Sobrio, F; Toutain, J; Valable, S | 1 |
| Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B | 1 |
1 trial(s) available for pyrroles and misonidazole
| Article | Year |
|---|---|
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
2 other study(ies) available for pyrroles and misonidazole
| Article | Year |
|---|---|
Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Topics: Angiogenesis Inhibitors; Animals; Biological Transport; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cerebrovascular Circulation; Disease Models, Animal; Glioma; Indoles; Kinetics; Magnetic Resonance Imaging; Misonidazole; Neovascularization, Pathologic; Permeability; Positron-Emission Tomography; Pyrroles; Rats; Sunitinib; Treatment Outcome | 2011 |
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib | 2015 |